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SPECIFIC AIM
The aim of this study is to demonstrate the feasibility of
naturally derived low molecular weight protamine as a
potential translocational domain for the intracellular
delivery of molecular medicine including macromolec-
ular drug (i.e., protein), therapeutic gene, or molecu-
lar diagnostic probes as well as nanoparticulates.
PRINCIPAL FINDINGS
1. Preparation of the low molecular weight protamine
sequences and their translocational capacity through
various types of cells as well as biocompatibility
LMWP fragments were derived from native protamine by
thermolysine digestion, which provided 5 different frac-
tions, denoted TDSP (thermolysin-digested segmented
protamine) 1 to 5 (PRRRR, PRRRRSSSRP, RPVR-
RRRRPR, VSRRRRRRGGRRR, VSRRRRRRGGRRRR)
depending on their elution order from a heparin
affinity chromatography. Except for TDSP1, which pos-
sessed less arginine residues than those required for
cell transduction, the cell internalization activity of
TDSPs 2, 3, 4, and 5 were all examined. All of the
studied LMWP peptides displayed sufficient cellular
uptake at 30 min after incubation in accordance with
the increase of the arginine content in these peptides.
The TDSP5 peptide further demonstrated the en-
hanced cellular uptake as cells transfected with TDSP5
exhibited the highest fluorescence intensity and was
largely localized in the cytoplasm of HeLa cells. Similar
results were also obtained by using other cell line types
including 293T, CT26, human MCF-7 cells, fibroblast,
as well as MG 63 osteoblasts. To evaluate the biocom-
patibility of LMWP as a translocational carrier, the
effect of serum on the transduction efficiency of LMWP
was conducted in cell culture medium containing 10%
fetal bovine serum. The efficiency of TDSP5 uptake was
not affected by the presence of serum. In addition,
these peptides showed no significant cytotoxicity (i.e.,
10% reduction in cell viability) up to a concentration
of 10 mM, whereas PEI, a common synthetic transfect-
ing agent, showed a significant decrease (40%) of cell
viability at or above a concentration of 5.0 mM.
2. Conjugation of LMWP to molecular probe and
protein enhances biologic activities
To examine whether LMWP could be used as a carrier
for intracellular delivery of cargo molecules for imag-
ing or therapeutic purpose, phalloidin or gelonin was
conjugated to LMWP. Each molecule was conjugated to
LMWP by 1:1 molar ratio (Fig. 1). The heparin column
elution profile of the reaction mixture provided 3
representative peaks: unreacted gelonin (1st peak),
LMWP-gelonin conjugate (2nd peak), unconjugated
LMWP, and the mixture of the conjugate with higher
amount of LMWP attached (3rd peak). We used the
sample from second peak (samples with 1:1 molar ratio
of LMWP and gelonin) for further study. The LMWP-
gelonin, TAT-gelonin, and gelonin had IC50 values of
23, 15, and 49 pM, respectively, indicating that con-
jugation of gelonin to both LMWP and TAT did not
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reduce the bioactivity of the toxin component of gelo-
nin.
To compare the translocation activity of LMWP with
other known protein transduction domains (PTDs),
HIV-TAT peptide was selected as a control and conju-
gated to gelonin. As shown by the FACS results (Fig. 1),
the ability to translocate gelonin by LMWP and TAT
was closely comparable. In both cases, rhodamine la-
bels were clearly detected after 30 min of incubation of
these peptides with CT-26 cells. Data from confocal
microscopic studies were also in agreement with the
FACS results, displaying a cytoplasmic localization of
the TDSP5-gelonin conjugates instead of adsorption to
the cell surfaces (Fig. 1). Cells treated with LMWP-
phalloidin conjugates exhibited quick and obvious cy-
toskeleton labeling without any permeabilization step
of the cell membranes (Fig. 1), while treating with
phalloidin could not label cells without permeabiliza-
tion (data not shown). To further confirm the LMWP-
gelonin conjugates actually penetrated into the tumor,
rhodamine-labeled gelonin was applied during in vivo
studies. The tumor tissues from LMWP-gelonin-treated
mice displayed a strong and uniform red staining from
rhodamine on the labeled LMWP-gelonin conjugates
(Fig. 1), implicitly confirming the penetration of the
LMWP-gelonin conjugate into the tumor tissues. Con-
versely, mice injected with rhodamine-labeled free ge-
lonin displayed virtually no or at most, a sporadic, weak
staining of rhodamine (Fig. 1). Therefore, antitumor
effect of LMWP-gelonin was anticipated by the results
from the enhanced distribution of the conjugates into
the tumor tissues.
Biological consequences of treating subcutaneous
solid tumors with LMWP-gelonin were assayed after
peritumoral injection of test samples. Mice treated with
Figure 1. A) Formation of LMWP-gelonin conjugates. Pre-
pared LMWP (TDSP5) -gelonin conjugate was purified from
unconjugated gelonin and LMWP by eluting through a
heparin-affinity chromatography column. Elution profiles
were followed by absorbance at 280nm. The Inset shows
molecular weight of LMWP-gelonin conjugates by SDS-PAGE
analysis. LMWP-gelonin conjugate and native gelonin were
examined by SDS-PAGE on a 12% gel, stained with Coomassie
brilliant blue. The left lane of the molecular marker indicates
the molecular weight of gelonin (29,000 Da), whereas the
right indicates LMWP-gelonin (31,000 Da). The molecular
weight marker ranges from 29,000 to 700,000. B) FACS
analysis of cell uptake by rhodamine-labeled LMWP-gelonin
conjugate and rhodamine-labeled TAT-gelonin conjugate in
CT-26 cell line (1106 cells/well) in the presence of 10%
serum. C) Cellular localization of rhodamine-labeled LMWP-
gelonin conjugates in CT-26 colon adenocarcinoma cells.
Rhodamine-labeled gelonin, LMWP-gelonin conjugate, and
TAT-gelonin conjugate were overlaid onto cultured CT-26
cells in the presence of 10% FBS. Cellular localization was
monitored by confocal microscopy. D) FACS analysis of cell
uptake by Alexa Fluoro488-labeled LMWP-phalloidin conju-
gate and TAT-phalloidin conjugate in MG63 osteoblast cells
(1106 cells/well) in the presence of 10% serum. Alexa
Fluoro488-labeld phalloidin was served as control. E) Cellular
localization of rhodamine-labeled LMWP-gelonin conjugates
in MG63 osteoblast cells. Rhodamine-labeled LMWP-phalloi-
din conjugate was overlaid onto cultured MG63 cells in the
presence of 10% FBS. Cellular localization was monitored by
confocal microscopy. F) Tumor penetration of rhodamine-
labeled free gelonin into the colon cancer and (G) rhoda-
mine-labeled LMWP-gelonin. The mice were then analyzed
for penetration extent with LMWP-gelonin conjugate
through the tumor. Tumors were isolated at 10 h after
injection of either rhodamine-labeled gelonin or rhodamine-
labeled LMNP-gelonin conjugate, cryosectioned, and photo-
graphed by confocal microscopy. Left panel: fluorescent
image of rhodamine labeled protein transduced in the tumor
tissue. Right panel: identical DIC mode.
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free gelonin did not display regression on tumor
growth, since gelonin could not penetrate the tumor.
An average tumor weight of 2.63  0.5 g was observed
4 wk after injection of gelonin. In a sharp contrast,
mice treated with the LMWP-gelonin conjugate dis-
played a significant regression in tumor growth, as
the tumor weight was reduced to an insignificant
value of 0.33  0.12 g. Addition of free LMWP to the
gelonin solution did not elicit any effect on tumor
regression, as an average tumor mass of 2.74  0.68 g
was observed 4 wk after treatment, clearly indicating
that only covalent conjugation of LMWP was able to
transduce gelonin and present the anti-tumor effect
with the same extent to that by TAT conjugate
(0.210.04 g).
CONCLUSIONS AND SIGNIFICANCE
Although the currently used protein transduction do-
main (PTD) peptides, including TAT, has great poten-
tial as a universal carrier for the intracellular delivery of
biomolecules, clinical applications of PTDs are hin-
dered by two major shortcomings. One is that many of
PTDs are primarily derived from highly infective viral
proteins, yet the toxicity and immunogeneicity profiles
of these peptides have not been established. The other
limitation is that PTDs are not naturally occurring
peptides and thus must be produced by synthetic
routes. Synthetic preparation of arginine rich peptides
has a shortcoming of low yields rendering it practically
difficult to meet with the demand for numerous clinical
applications. To this regard, the most significant, novel
finding of this study is that the freely modifiable
potential translocation domain peptide can be derived
from natural protamine by enzymatic digestion. The in
vitro and in vivo results have demonstrated that LMWP,
especially TDSP5, is as potent a cell transduction pep-
tide as any existing PTD including TAT. Yet, the
presence of thoroughly established toxicological and
immunological profiles, the derivation from a natural
resource, and the suitability and ease for manufactur-
ing mass quantities would render LMWP to become the
most preferable choice among current PTDs for impor-
tant clinical applications including molecular probes,
protein, gene, and virtually all types of medical imaging
and drug therapies. Aside from these direct clinical
utilities, the universal applicability of LMWP to trans-
duce all types of compounds into cells regardless their
physical and chemical attributes (i.e., small or large,
hydrophilic or hydrophobic) could enable the discov-
ery and/or development of new therapeutic or imaging
agents that are initially considered unusable due to
their inability to enter the cells (Fig. 2). Two major
potential application of LMWP are described in Fig. 2.
One is for molecular medical imaging of probes by
conjugating with LMWP. The labeled probes can inter-
act with intracellular target when they are conjugated
with transduction carrier, LMWP. LMWP-probe conju-
gates can translocalize through the target organ, which
enables real-time in vivo imaging without sacrifice of
animal. The other possible application of LMWP is as a
carrier for therapeutic proteins or genetic materials
including DNA and RNA, which by themselves cannot
cross the cell membranes or disease site such as solid
tumor mass. The anticancer protein drug, as an exam-
ple, by itself could not provide with such significant
anticancer efficacy, however, can be transduced only
after conjugation with LMWP, which presents marked
anticancer activity. The insensitivity of cell uptake against
the presence of serum and cell viability could also allow
LMWP to be used in the screening of potential therapeu-
tic proteins, investigating protein–protein interaction
in the cells, screening of potential therapeutic proteins
and elucidating the role of proteins in certain specific
disease development. Taken together, naturally derived
nontoxic LMWP was suggested as a potential tool for
carrying any biologic molecules to enhance the thera-
peutic or diagnostic efficacy.
Figure 2. Possible application strategy of pre-
pared LMWP: 1) to enhance the molecular
medical imaging efficiency by directly deliver-
ing probe molecules into the cells or organs;
and 2) to improve bioavailability of poorly pen-
etrating/absorbed protein or genetic drug by
conjugating with LMWP. Pictures were taken
from mouse administered with LMWP-gelonin
conjugate or gelonin 2 wk after injection. Note
the significant marginal tumor mass of the
mouse treated with LMWP-gelonin conjugate
while the mouse treated with gelonin showed
larger mass.
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